IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HRâ+â/HER2-negative metastatic breast cancer.
IL-6 预测 CDK4/6 抑制剂耐药性，确定 STAT3 为 HR+/HER2 阴性转移性乳腺癌的靶点
期刊:npj Precision Oncology
影响因子:8
doi:10.1038/s41698-025-01041-1
Kettner Nicole M, Bui Tuyen N, Navarro-Yepes Juliana, Ghotbaldini Sanaz, Quintela Bethanie, Luo Catherine K, Lam Nghi, Rao Xiayu, Raghavendra Akshara Singareeka, Wang Yan, Azizian Nancy, Kris Eckols T, Kasembeli Moses Makokha, Evans Kurt, Yi Min, Wingate Hannah, Wang Jing, Sahin Aysegul A, Meric-Bernstam Funda, Hunt Kelly K, Damodaran Senthil, Tweardy David J, Tripathy Debu, Keyomarsi Khandan
